TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.
Ajit Parhi, PhD
Advertisement
Parhi is the Chief Scientific Officer of TAXIS Pharmaceuticals.
Articles by Ajit Parhi, PhD
Advertisement
Latest Updated Articles
A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant GonorrheaPublished: July 14th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol is Noninferior, But not "Game-Changer," for Gram-negative Bloodstream Infections
2
As NDM-CRE Infections Rise Significantly, Diagnostic Access Emerges as Weak Link
3
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
4
Misdiagnosis Common in Skin Infections Due to Overlapping Noninfectious Conditions
5
